Image pharmaphorum Editor Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars? Debates & Insight Sponsored Powering pharma’s commercial teams with market access insigh... Debates & Insight Sponsored Powering the life sciences commercial engine with market acc... Views & Analysis Clinical trials: realising the untapped potential Winning proposal to create a corporate social responsibility (CSR) programme. Load more results
Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars?
Views & Analysis Clinical trials: realising the untapped potential Winning proposal to create a corporate social responsibility (CSR) programme.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.